Abstract
Protein Tyrosine kinases (TKs) play important roles in regulating the most fundamental cell processes, such as the cell cycle, proliferation, differentiation, motility, and cell death or survival. In many tumor cells, key TKs may no longer be adequately controlled, and excessive phosphorylation sustains signal transduction pathways in an activated state. Imatinib mesylate is an oral multitargeted tyrosine kinase inhibitor with antitumor activity. It recently received approval from the US Food and Drug Administration for the treatment of patients with BCR/ABL translocation defining chronic myeloid leukaemia, and subsequently for the treatment of patients with KIT (CD117)-positive non-resectable and/or metastatic malignant gastrointestinal stromal tumors. It has also shown promising clinical activity against other advanced solid tumors. The review provides an updated summary of emerging clinical experience with this promising new anticancer agent.
Keywords: Tyrosine kinases, imatinib mesylate, targeted-therapy, ABL-BRL, c-kit, solid tumors
Current Enzyme Inhibition
Title: Imatinib Mesylate for the Treatment of Solid Tumours: Recent Trials and Future Directions
Volume: 3 Issue: 4
Author(s): Carlo Smirne, Anna Carbone, Tiziana Scirelli and Graziella Bellone
Affiliation:
Keywords: Tyrosine kinases, imatinib mesylate, targeted-therapy, ABL-BRL, c-kit, solid tumors
Abstract: Protein Tyrosine kinases (TKs) play important roles in regulating the most fundamental cell processes, such as the cell cycle, proliferation, differentiation, motility, and cell death or survival. In many tumor cells, key TKs may no longer be adequately controlled, and excessive phosphorylation sustains signal transduction pathways in an activated state. Imatinib mesylate is an oral multitargeted tyrosine kinase inhibitor with antitumor activity. It recently received approval from the US Food and Drug Administration for the treatment of patients with BCR/ABL translocation defining chronic myeloid leukaemia, and subsequently for the treatment of patients with KIT (CD117)-positive non-resectable and/or metastatic malignant gastrointestinal stromal tumors. It has also shown promising clinical activity against other advanced solid tumors. The review provides an updated summary of emerging clinical experience with this promising new anticancer agent.
Export Options
About this article
Cite this article as:
Smirne Carlo, Carbone Anna, Scirelli Tiziana and Bellone Graziella, Imatinib Mesylate for the Treatment of Solid Tumours: Recent Trials and Future Directions, Current Enzyme Inhibition 2007; 3 (4) . https://dx.doi.org/10.2174/157340807782330246
DOI https://dx.doi.org/10.2174/157340807782330246 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Design, Synthesis and Biochemical Evaluation of Estrogen Receptor Ligand Conjugates as Tumour Targeting Agents
Letters in Drug Design & Discovery Naturally Occuring Pyrrolo[1,4]benzodiazepines in Bacteria
Mini-Reviews in Organic Chemistry Anticancer Properties of Flavonoids: Roles in Various Stages of Carcinogenesis
Cardiovascular & Hematological Agents in Medicinal Chemistry Combinations of Plant Polyphenols & Anti-Cancer Molecules: A Novel Treatment Strategy for Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry The MYC Oncogene as a Cancer Drug Target
Current Cancer Drug Targets Insights into the Biological Evaluation of Pterocarpanquinones and Carbapterocarpans with Anti-tumor Activity against MDR Leukemias
Anti-Cancer Agents in Medicinal Chemistry Structure and Ligand-based Design of P-glycoprotein Inhibitors: A Historical Perspective
Current Pharmaceutical Design Anticancer Drugs Discovery and Development from Marine Organisms
Current Topics in Medicinal Chemistry Potentials of Hydrogels in Cancer Therapy
Current Cancer Therapy Reviews Mitochondrial Tolerance to Drugs and Toxic Agents in Ageing and Disease
Current Drug Targets Gene Therapy Approaches in an Autoimmune Demyelinating Disease: Multiple Sclerosis
Current Gene Therapy Recent Progress in Research on Ribosome Inactivating Proteins
Current Protein & Peptide Science Cancer Stem Cells in Prostate Cancer Chemoresistance
Current Cancer Drug Targets Plasticity and Maintenance of Hematopoietic Stem Cells During Development
Recent Patents on Biotechnology What Does Systems Biology Mean for Drug Development?
Current Medicinal Chemistry Dedication to Professor Tony Dodi
Current Cancer Therapy Reviews Current and Emerging Strategies in Bladder Cancer
Anti-Cancer Agents in Medicinal Chemistry Nelarabine- A New Purine Analog in the Treatment of Hematologic Malignancies
Reviews on Recent Clinical Trials Heat Shock Protein 90 Inhibitors in Oncology
Current Proteomics Targeting Schistosome Histone Modifying Enzymes for Drug Development
Current Pharmaceutical Design